ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
Phase 1
- Conditions
- Melanoma, Renal cell carcinomaTherapeutic area: Diseases [C] - Neoplasms [C04]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Age = 18 years, Advanced or metastatic melanoma or RCC, Current treatment with nivolumab in a 6 mg/kg or 480 mg, 4 weekly scheme, Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1, On treatment for at least 6 months
Exclusion Criteria
Unable to draw blood for study purposes, Patients willing to participate or already included in the SAFE-STOP trial
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method